1. Home
  2. Staff
  3. University Academic Staff
  4. Prof LUI Tak Wai David Profile

Professor LUI Tak Wai, David

Prof David Lui

Clinical Assistant Professor

  • MBBS (Hons) (HK); MRCP (UK); FHKCP; FHKAM (Medicine)
email dtwlui@hku.hk
email 2255-4704
email HKU Scholars Hub
Personal Page: https://orcid.org/0000-0002-9813-1126
Citation Report: https://www.webofscience.com/wos/author/record/2101206
Biography
Prof David Lui obtained his MBBS degree with Honours from the University of Hong Kong and completed his specialty training in Endocrinology, Diabetes, and Metabolism at Queen Mary Hospital. He joined the Department of Medicine at the University of Hong Kong as a Clinical Assistant Professor in March 2021.

His research interests include bone and muscle health in diabetes, dyslipidaemia in diabetes, and endocrine epidemiology and pharmacoepidemiology. Supported by the Health and Medical Research Fund, he is leading a randomized controlled trial on the effects of statins on bone health in postmenopausal women with type 2 diabetes, studying the epidemiology of fractures in type 2 diabetes within Hong Kong, and examining the long-term impacts of COVID-19 on metabolic disorders. Dr. Lui has established cohorts to evaluate bone and muscle health in individuals with and without diabetes and has contributed to the development of the 2024 OSHK Guideline for the Clinical Management of Postmenopausal Osteoporosis in Hong Kong, particularly the section on ‘Diabetes and Osteoporosis’. Additionally, he was a visiting fellow at the University of New South Wales, Sydney, during 2024/25, where he studied high-density lipoprotein function in type 2 diabetes under the mentorship of Professor Kerry Rye.

He has authored over 100 peer-reviewed articles in international journals, including Nature Reviews Endocrinology, Diabetes Care, EClinicalMedicine, JAMA Surgery, and JAMA Network Open. Two of his publications have been listed among the Highly Cited Papers in the Essential Science Indicators (ESI). In recognition of his research contributions, he has received numerous awards, including the Distinguished Research Paper Award for Young Investigators from the Hong Kong College of Physicians (2021, 2022, and 2023) and the Rising Star Award at the International Congress of Diabetes and Metabolism (2021). He currently serves on the Editorial Boards of The Journal of Clinical Endocrinology and Metabolism and Endocrine Practice. He is an active member of the Asia-Pacific Consortium on Osteoporosis (APCO) and the Asia-Pacific Cardio-Metabolic Consortium (APCMC).


Research Profile
  • Bone and mineral metabolism: bone and muscle health in diabetes; primary hyperparathyroidism and hypoparathyroidism
  • Lipidology: dyslipidaemia and high-density lipoprotein function in diabetes
  • Pharmacoepidemiology in diabetes: big data analysis
  • Endocrine epidemiology: endocrine disorders in COVID-19; adrenal disorders


Selected publications
  1. Lui DTW, Lee CH, Woo YC, Hung IFN, Lam KSL. Thyroid dysfunction in COVID-19. Nat Rev Endocrinol. 2024;20(6):336-348. (2024 JIF: 40.0)
  2. Lui DTW, Tang EHM, Au ICH, Wu T, Lee CH, Wong CK, Cheung CYY, Fong CHY, Chow WS, Woo YC, Tan KCB, Lam KSL, Wong CKH. Evaluation of fracture risk among type 2 diabetes patients with non-valvular atrial fibrillation receiving different oral anticoagulants. Diabetes Care. 2022;45(11):2620-2627. (2024 JIF: 16.6)
  3. Lui DTW, Cheung CL, Lee ACH, Wong Y, Shiu SWM, Tan KCB. Carbamylated HDL and mortality outcomes in type 2 diabetes. Diabetes Care. 2021;44(3):804-809. (2024 JIF: 16.6)
  4. Liu X*, Lui DTW*,#, Xiong X, Li L, Luk Y, Wong CH, Lee CH, Wong CKH, Fung MMH, Lang BHH#. Parathyroidectomy and risk of incident diabetes in patients with primary hyperparathyroidism. JAMA Surg. Published online August 27, 2025. (2024 JIF: 14.9; *co-first author, #co-corresponding author)
  5. Lui DTW, Tang EHM, Wu T, Au ICH, Lee CH, Woo YC, Tan KCB, Wong CKH. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based study in Hong Kong. Cardiovascular Diabetology. 2023;22(1):40. (2024 JIF: 10.6)
  6. Wong CKH, Lau KTK, Tang EHM, Lee CH, Lee CYY, Woo YC, Tan KCB, Lui DTW. Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study. Cardiovascular Diabetology. 2022;21(1):92. (2024 JIF: 10.6; corresponding author)
  7. Lui DTW, Au ICH, Tang EHM, Cheung CL, Lee CH, Woo YC, Wu T, Tan KCB, Wong CKH. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: a real-world population-based analysis. EClinicalMedicine. 2022;50:101510. (2024 JIF: 10.0)
  8. Xiong X*, Lui DTW*, Chung MSH, Au ICH, Lai FTT, Wan EYF, Chui CSL, Li X, Cheng FWT, Cheung CL, Chan EWY, Lee CH, Woo YC, Tan KCB, Wong CKH, Wong ICK. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: a population-based cohort study. PLoS Med. 2023;20(7):e1004274. (2024 JIF 9.9; *co-first author)
  9. Lui DTW, Chung MSH, Lau EHY, Lau KTK, Au ICH, Lee CH, Woo YC, Wong CKH, Cowling BJ. Analysis of all-cause hospitalization and death among non-hospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir and nirmatrelvir-ritonavir during the Omicron wave in Hong Kong. JAMA Netw Open. 2023;6(5):e2314393. (2024 JIF 9.7)
  10. Lui DTW, Lee CH, Wong Y, Fong CHY, Tsoi KH, Woo YC, Tan KCB. A prospective one-year follow-up of glycaemic status and C-peptide levels of COVID-19 survivors with dysglycaemia in acute COVID-19 infection. Diabetes Metab J. 2024;48(4):763-770. (2024 JIF: 8.5)
  11. Lui DTW, Li L, Liu X, Xiong X, Tang EHM, Lee CH, Woo YC, Lang BHH, Wong CKH, Tan KCB. The association of HDL-cholesterol levels with incident major adverse cardiovascular events and mortality in 0.6 million individuals with type 2 diabetes. BMC Med. 2024;22(1):586. (2024 JIF: 8.3)
  12. Wong CKH*, Lui DTW*, Xiong X*, Chui CSL, Lai FTT, Li X, Wan EYF, Cheung CL, Lee CH, Woo YC, Au ICH, Chung MSH, Cheng FWT, Tan KCB, Wong ICK. Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients. BMC Med. 2022;20(1):339. (2024 JIF: 8.3; *co-first author)
  13. Xiong X, Wong CKH, Au ICH, Lai FTT, Li X, Wan EYF, Chui CSL, Chan EWY, Cheng FWT, Lau KTK, Lee CH, Woo YC, Lui DTW*, Wong ICK*. Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study. Thyroid. 2022;32(5):505-514. (2024 JIF 6.7; *co-corresponding author) (ESI Highly Cited Paper; Thyroid® The Top-Read Articles of 2022)
  14. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Thyroid Dysfunction in Relation to Immune Profile, Disease Status and Outcome in 191 Patients with COVID-19. J Clin Endocrinol Metab. 2021;106(2):e926-e935. (2024 JIF: 5.0) (ESI Highly Cited Paper; JCEM Highly Cited Articles 2019-2021; top 10% of articles published in JCEM in 2020-2021 & 2021-2022)
  15. Lui DTW, Lee CH, Cheung CYY, Mak JHC, Fong CHY, Lui BWC, Cheung VSY, Chow WS, Lee ACH, Tam AR, Pang P, Ho TY, Tan KCB, Woo YC, Hung IFN, Lam KSL. Effect of COVID-19 vaccines on thyroid function and autoimmunity and effect of thyroid autoimmunity on antibody response. J Clin Endocrinol Metab. 2022;107(9):e3781-e3789. (2024 JIF: 5.0; first and corresponding author) (Top 10% of articles published in JCEM in 2021-2022)
  16. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Insights from prospective follow-up of thyroid function and autoimmunity among COVID-19 survivors. Endocrinol Metab (Seoul). 2021;36(3):582-589. (2024 JIF: 4.2) (Top-cited paper in EnM 2021-2022 in the field of thyroid)
  17. Lui DTW, Lee ACH, Tan KCB. Management of familial hypercholesterolemia: current status and future perspectives. J Endocr Soc. 2020;5(1):bvaa122. (2024 JIF: 3.0) (Endocrine Society Thematic Issue on Lipids and Adipocytes 2021; top 10% of articles published in JES in 2021-2022)
  18. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Role of non-thyroidal illness syndrome in predicting adverse outcomes in COVID-19 patients predominantly of mild to moderate severity. Clin Endocrinol (Oxf). 2021;95(3):469-477. (2024 JIF: 2.4) (Top Cited Article 2020-2021 & 2021-2022 in Clinical Endocrinology)

Awards
  • Travel Grant Award (Outstanding Class), International Congress of Diabetes and Metabolism (2024)
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2023)
  • Merit Abstract Award in Clinical Research, 28th Medical Research Conference (2023)
  • Li Ka Shing Medical Fellowship for Internal Medicine (2023)
  • Faculty Outstanding Research Output Award, HKUMed (2022)
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2022) (with Best Presenter Award)
  • ISE Abstract Award, 20th International Congress of Endocrinology (2022)
  • Endocrine Society Outstanding Abstract Award, ENDO 2022 (2022)
  • Best Abstract in Clinical Medicine (Poster), 27th Medical Research Conference (2022)
  • Best Poster Exhibition Award in 9th Seoul International Congress of Endocrinology and Metabolism (2021)
  • Rising Star Award, International Congress of Diabetes and Metabolism (2021)
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2021)
  • Best Abstract in Clinical Medicine (Oral), 26th Medical Research Conference (2021)
  • International Non-Fellow Physician AACE Travel Grant Award, AACE 29th Annual Scientific & Clinical Congress (2020)
  • Poster Award, Asia Islet Biology & Incretin Symposium (2019)
  • Best Abstract in Clinical Medicine (Poster), 24th Medical Research Conference (2019)

Grant Record
External competitive grants as Principal Investigator
  • Health and Medical Research Fund 2022 – Risks and burdens of metabolic sequelae in long COVID: focusing on glucose, lipid and bone metabolism (Ref: 21222081; HKD 1,493,807)
  • Health and Medical Research Fund 2021 – Fragility fractures in type 2 diabetes as an emerging diabetic complication: epidemiology, burden and strategies of primary prevention (Ref: 20211971; HKD 678,248)
  • Health and Medical Research Fund 2020 – The effect of simvastatin on bone density in postmenopausal women with type 2 diabetes: a double-blind, randomized, active-comparator (ezetimibe) controlled clinical trial (Ref: 19200931; HKD 1,478,393)



Key Office
  • Secretary, Diabetes Division of Hong Kong Society of Endocrinology, Metabolism and Reproduction (2025 – now)
  • Executive Committee Member, Asia Pacific Consortium on Osteoporosis (2025 – now)
  • Communications Workgroup Co-Lead, Asia Pacific Cardiometabolic Consortium (2025 – now)
  • Young Fellow, Specialty Board of Endocrinology, Diabetes and Metabolism, Hong Kong College of Physician (2025 – now)
  • Member, Editorial Board, AACE Endocrinology and Diabetes (2025 – now)
  • Member, Editorial Board, The Journal of Clinical Endocrinology and Metabolism (2024 – now)
  • Member, Editorial Board, Endocrine Practice (2024 – now)
  • Director, Osteoporosis Centre, The University of Hong Kong (2024 – now)